Conversion to Aumolertinib in NSCLC Patients with EGFR Mutations Who Are Safety Intolerant after Osimertinib Treatment: A Retrospective Study

被引：0
|
作者：
Yao, B. [1 ]
Yang, L. F. [1 ]
Ran, T. [1 ]
Deng, S. [1 ]
Xu, Q. [1 ]
机构：
[1] Tongren City Peoples Hosp, Tongren, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
osimertinib; aumolertinib; safety intolerant;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP12.01-63
引用
收藏
页码：S666 / S667
页数：2
相关论文
共 50 条
  • [21] Impact of Clinicopathological Features on Efficacy of Osimertinib in Advanced NSCLC Patients With EGFR Mutations
    Wang, Y.
    Wang, Y.
    Tian, P.
    Han, R.
    Li, L.
    He, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S585 - S585
  • [22] A Retrospective Study of Aumolertinib Monotherapy or Combination Therapy Treated EGFR-mutated NSCLC Patients with Leptomeningeal Metastases
    Huang, S.
    Li, L.
    Yan, N.
    Zhang, H.
    Guo, S.
    Guo, Q.
    Geng, D.
    Li, X.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S433 - S433
  • [23] Safety and efficacy of osimertinib in patients with NSCLC and uncommon tumoral EGFR mutations: A systematic review and meta-analysis
    Priantti, Jonathan N.
    Vilbert, Maysa
    Moraes, Francisco Cezar A.
    Michelon, Isabella
    Castro, Caio
    Leighl, Natasha B.
    Cavalcante, Ludimila
    Fujiwara, Yu
    Addeo, Alfredo
    Bar, Jair
    Cortellini, Alessio
    Nassar, Amin
    Naqash, Abdul Rafeh
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [24] Outcomes in NSCLC Patients with EGFR Co-Mutations Receiving Aumolertinib as First-Line Treatment: the Updated Results
    Fang, S.
    Xu, T.
    Liu, N.
    Wang, X. Y.
    Cheng, W. W.
    Fang, H. H.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S650 - S650
  • [25] A Retrospective Study of Aumolertinib in Combination with Bevacizumab for EGFR-mutated NSCLC with the Presence of Leptomeningeal Metastasis
    Fang, S.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S422 - S422
  • [26] Safety of tepotinib plus EGFR TKI (osimertinib or gefitinib) in patients with EGFRm NSCLC
    Nadal, E.
    Kim, T. M.
    Guarneri, V.
    Voon, P. J.
    Lim, B. K.
    Wislez, M.
    Huang, C.
    Liam, C. K.
    Mazieres, J.
    Tho, L. M.
    Hayashi, H.
    Nguyen, N.
    Chia, P. L.
    De Marinis, F.
    Brutlach, S.
    Adrian, S.
    Ellers-Lenz, B.
    Berghoff, K.
    Karachaliou, N.
    Wu, Y-L.
    ANNALS OF ONCOLOGY, 2023, 34
  • [27] Usage of Radiotherapy With Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations
    不详
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (01) : E3 - E4
  • [28] Efficacy and Safety of Aumolertinib with Radiotherapy in the Treatment of Unresectable Locally Advanced EGFR-Mutant NSCLC: A Phase II Study
    Meng, X.
    Kong, L.
    Zhao, K.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S581 - S581
  • [29] High-dose aumolertinib versus osimertinib in EGFR T790M+NSCLC patients with brain metastases (ATTACK)
    Lu, S.
    Han, L.
    Lv, D.
    Zhang, Z.
    Wu, J.
    Wang, Q.
    Dong, X.
    Hu, Y.
    Chen, J.
    Wu, L.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S86 - S86
  • [30] First-line osimertinib for patients with advanced NSCLC harboring EGFR mutations: A real-world study
    Ji, W.
    Jiang, D.
    Zhang, J.
    Zhang, H.
    Wang, Q.
    Cang, S.
    Li, X.
    Tan, J.
    Xiang, Y.
    Li, X.
    Liu, A.
    Lu, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S1693 - S1693
12345